within Pharmacolibrary.Drugs.ATC.S;

model S01XA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.0002,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01XA10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Inosine is a purine nucleoside that forms when hypoxanthine is attached to a ribose ring via a β-N9-glycosidic bond. It has been investigated for several indications, including ophthalmic use as a cytoprotective and metabolic enhancer (mainly in Eastern Europe and Russia), and as an adjunct in neurology (such as in multiple sclerosis and Parkinson's disease investigational studies). Inosine is not approved for widespread therapeutic use in most countries but may be used in some as a supportive or off-label medication.</p><h4>Pharmacokinetics</h4><p>No formal published pharmacokinetic (PK) parameters are available for inosine in humans or in published ophthalmic studies; estimates are provided based on analogous nucleoside compounds and general pharmacokinetic principles.</p><h4>References</h4><ol><li><p>Wientjes, MG, &amp; Au, JL (1992). Pharmacokinetics of oral 2&#x27;,3&#x27;-dideoxyinosine in rats. <i>Pharmaceutical research</i> 9(6) 822–825. DOI:<a href=\"https://doi.org/10.1023/a:1015872026094\">10.1023/a:1015872026094</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1409368/\">https://pubmed.ncbi.nlm.nih.gov/1409368</a></p></li><li><p>Shelton, MJ, et al., &amp; Morse, GD (1992). Didanosine. <i>The Annals of pharmacotherapy</i> 26(5) 660–670. DOI:<a href=\"https://doi.org/10.1177/106002809202600511\">10.1177/106002809202600511</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1350471/\">https://pubmed.ncbi.nlm.nih.gov/1350471</a></p></li><li><p>Hashimoto, M, et al., &amp; Otagiri, M (2018). Pharmacokinetic properties of a novel inosine analog, 4&#x27;-cyano-2&#x27;-deoxyinosine, after oral administration in rats. <i>PloS one</i> 13(6) e0198636–None. DOI:<a href=\"https://doi.org/10.1371/journal.pone.0198636\">10.1371/journal.pone.0198636</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29874291/\">https://pubmed.ncbi.nlm.nih.gov/29874291</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01XA10;
